RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Scope of the Report:
RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.
At present, global expenses concentrates i ...
Table of Contents
1 RNAi for Therapeutic Market Overview
1.1 Product Overview and Scope of RNAi for Therapeutic
1.2 Classification of RNAi for Therapeutic by Types
1.2.1 Global RNAi for Therapeutic Revenue Comparison by Types (2019-2024)
1.2.2 Global RNAi for Therapeutic Revenue Market Share by Types in 2018
1.3 Global RNAi for Therapeutic Market by Application
1.3.1 Global RNAi for Therapeutic Market Size and Market Share Comparison by Applications (2014-2024)
1.4 Global RNAi for Therapeutic Market by Regions
1.4.1 Global RNAi for Therapeutic Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) RNAi for Therapeutic Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) RNAi for Therapeutic Statu ...